Krebs Biochemicals & Industries
KREBSBIO NSE
Krebs Biochemicals & Industries
HealthcareNSE: KREBSBIO BSE: 524518 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹130 Cr
Volatility
Moderate
P/E Ratio
-9.4
EBITDA
₹-5.45 Cr
Return on Equity
18.42%
Debt to Equity
0
Book Value
₹-75.49
52W High
₹82.49
52W Low
₹38.33
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -15.1% over past five years.
Growth Rate
Revenue Growth
-46.07% lower than
3Y
Net Income Growth
-37.06% lower than
3Y
Cash Flow Change
-434% lower than
3Y
ROE
11.3% lower than
3Y
ROCE
148% higher than
3Y
EBITDA Margin (Avg.)
-34.95% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.1 | 5.48 | 4.17 | 7.27 | 6.81 | 6.98 |
| Expenses | 13.2 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 | 6.97 | 7.67 | 6.16 |
| Operating Profit | -2.62 | -0.9 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 | -2.8 | 0.3 | -0.86 | 0.82 |
| OPM % | -24.76% | -6.04% | -16.1% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% | -67.15% | 4.13% | -12.63% | 11.75% |
| Other Income | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 | 0 | 2 | 0.16 |
| Interest | 1.1 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 | 1.79 | 1.91 | 1.88 |
| Depreciation | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.6 | 1.62 | 1.63 | 1.57 | 1.59 |
| PBT | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 | -6.14 | -3.12 | -2.34 | -2.49 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.24% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 | -6.14 | -3.13 | -2.34 | -2.48 |
| EPS in Rs | -2.47 | -1.66 | -2.31 | -2.71 | -2.4 | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 |
Profit & Loss
| Particulars | Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 24 | 25 |
| Expenses | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 29 | 28 |
| Operating Profit | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -5 | -3 |
| OPM % | — | -1088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -23% | -10% |
| Other Income | 3 | 1 | 0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 2 |
| Interest | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 | 7 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 6 | 6 |
| PBT | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 | -14 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 | -14 |
| EPS in Rs | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.5 | -7.85 | -6.54 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 9 | 0 | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 | -184 |
| Borrowings | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 225 |
| Other Liabilities | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 101 |
| Total Liabilities | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
| Fixed Assets | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 142 |
| CWIP | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total Assets | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -45 | -15 | -11 | -6 | 4 | -36 | -15 | -17 | -25 | 2 | -8 | -2 |
| Investing | -3 | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 | -5 | -4 |
| Financing | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 | 6 |
| Net Cash Flow | 6 | -6 | 0 | 0 | 17 | -17 | 1 | -1 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -48 | -23 | -17 | -9 | -1 | -45 | -40 | -41 | -36 | -5 | -11 | -5 |
| CFO/OP | 924 | 123 | 140 | 83 | -40 | 191 | 83 | 51 | 157 | -27 | 52 | 35 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | 0 |
| Inventory Days | — | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | — |
| Days Payable | — | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | — |
| Cash Conversion Cycle | — | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | 0 |
| Working Capital Days | — | -6,532 | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | -1,593 |
| ROCE % | -8% | -26% | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% | -15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Krebs Biochemicals & Industries insights
60 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR) Regulations, 2015.
7 May - Board meeting on May 21, 2026 to consider audited Q4 and FY2026 results. 7 May - Board meeting on May 21, 2026 to consider audited Q4 and FY2026 results.
2
Clarification On Price Movement
10 Apr - Company clarified on April 10, 2026 that no material event caused the price movement. 10 Apr - Company clarified on April 10, 2026 that no material event caused the price movement.
3
Clarification Sought from Krebs Biochemicals & Industries Ltd
8 Apr - Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure … 8 Apr - Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure …
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Company has enclosing herewith certificate received from RTA under reg 74 (5) of SEBI DP Regulations, 2018 for the quarter ended 31.03.2026. 7 Apr - Company has enclosing herewith certificate received from RTA under reg 74 (5) of SEBI DP Regulations, 2018 for the quarter ended 31.03.2026.
5
Closure of Trading Window
19 Mar - Trading window closed from COB March 31, 2026 until 48 hours after audited FY2026 results; board date to be notified. 19 Mar - Trading window closed from COB March 31, 2026 until 48 hours after audited FY2026 results; board date to be notified.
Frequently Asked Questions about Krebs Biochemicals & Industries
What does Krebs Biochemicals & Industries Ltd do?
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
Where is Krebs Biochemicals & Industries Ltd (KREBSBIO) listed?
Krebs Biochemicals & Industries Ltd trades as KREBSBIO on the NSE and under code 524518 on the BSE.
Which sector does Krebs Biochemicals & Industries Ltd belong to?
Krebs Biochemicals & Industries Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd has a market capitalisation of ₹130.48 Cr, which places it in the Small Cap band.
What is the PE ratio of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd trades at a PE ratio of -9.40, against a book value of ₹-75.49 per share.
What is the 52-week high and low of Krebs Biochemicals & Industries Ltd?
Over the last 52 weeks Krebs Biochemicals & Industries Ltd has traded between ₹38.33 and ₹82.49.
What is the Return on Equity (ROE) of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd reported a return on equity of 18.42%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KREBSBIO.md for Krebs Biochemicals & Industries Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.